Qingdao Haier Biomedical Co Ltd (688139) — Capital Reinvestment Ratio

Latest as of June 2023: 7.36x

Qingdao Haier Biomedical Co Ltd (688139) has a Capital Reinvestment Ratio of 7.36x as of June 2023, meaning it reinvests 7% of its operating cash flow (CN¥7.33 Million) in capital expenditures (CN¥53.93 Million). See 688139 equity financing ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

7.36x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥7.33 Million
CNY

Capital Expenditures

CN¥53.93 Million
CNY

Data as of

Jun 2023
Most recent filing

Qingdao Haier Biomedical Co Ltd Capital Reinvestment Ratio (2016–2025)

This chart tracks Qingdao Haier Biomedical Co Ltd's Capital Reinvestment Ratio across 10 annual periods. Check how aggressively does Qingdao Haier Biomedical Co Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Qingdao Haier Biomedical Co Ltd (2016–2025)

Year-by-year Capital Reinvestment Ratio for Qingdao Haier Biomedical Co Ltd from 2016 to 2025. For live market cap and broader valuation context, see Qingdao Haier Biomedical Co Ltd (688139) total market value.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 0.45x CN¥267.89 Million CN¥119.25 Million ▲ +2.5%
2024 0.43x CN¥291.67 Million CN¥126.70 Million ▼ -38.9%
2023 0.71x CN¥249.26 Million CN¥177.18 Million ▲ +52.8%
2022 0.47x CN¥632.43 Million CN¥294.24 Million ▲ +43.8%
2021 0.32x CN¥632.43 Million CN¥204.69 Million ▲ +153.4%
2020 0.13x CN¥696.62 Million CN¥88.99 Million ▼ -78.7%
2019 0.60x CN¥280.49 Million CN¥168.40 Million ▲ +29.0%
2018 0.47x CN¥149.00 Million CN¥69.33 Million ▲ +155.8%
2017 0.18x CN¥148.32 Million CN¥26.98 Million ▲ +176.8%
2016 0.07x CN¥220.72 Million CN¥14.50 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow